As investors and executives, we must stop asking "Is this drug safe?" and start asking "What is the drag coefficient?" Because a cure that arrives 5 years late is not a cure—it is a business decision.
This post is structured for a professional audience (LinkedIn, industry blog, or investor newsletter) but is written to be accessible to anyone following biotech. In the golden era of genetic medicine and AI-driven discovery, it takes an average of 10-15 years and $2.6 billion to bring a single drug to market. While we often blame the science for this timeline, a growing body of evidence points to a different culprit: Drag Pharma.
No, this isn't a new autoimmune disease. It is the silent, systemic friction that slows down the drug development pipeline—often deliberately.
Disclaimer: This post is for informational purposes only and does not constitute legal or investment advice.
"Drag Pharma" describes the strategic, operational, and regulatory inertia that incumbents (Big Pharma) use to protect market share, or the unintended consequences of bureaucracy that stifle innovation. It is the art of not moving quickly.
Karya Umum 
Filsafat 
Agama 
Ilmu-ilmu Sosial 
Bahasa 
Ilmu-ilmu Murni 
Ilmu-ilmu Terapan 
Kesenian, Hiburan, dan Olahraga 
Kesusastraan 
Geografi dan Sejarah